中東呼吸器症候群（MERS）は、コロナウイルス（MERS-CoV）によって引き起こされるウイルス性呼吸器疾患です。症状としては、発熱、咳、息切れなどがあります。その他の症状として、吐き気、嘔吐、下痢などがあります。肺炎を起こすことが多く、腎臓などの臓器に損傷を与えることもあります。治療は、輸液や薬で症状（関節痛や発熱）を和らげることが目的です。
目次
Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Middle East Respiratory Syndrome (MERS) - Overview
Middle East Respiratory Syndrome (MERS) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Middle East Respiratory Syndrome (MERS) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Middle East Respiratory Syndrome (MERS) - Companies Involved in Therapeutics Development
Middle East Respiratory Syndrome (MERS) - Drug Profiles
Middle East Respiratory Syndrome (MERS) - Dormant Projects
Middle East Respiratory Syndrome (MERS) - Discontinued Products
Middle East Respiratory Syndrome (MERS) - Product Development Milestones
Featured News & Press Releases
Oct 31, 2022: EpiVax joins Intravacc, CEPI on project to develop universal betacoronavirus vaccine
Nov 04, 2021: Vaccitech announces publication of second phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirus
Jun 14, 2021: Announcement of the effect of OBP-2011 against SARS and MERS
Feb 23, 2021: Monoclonal antibody REGN3051 against MERS coronavirus show promise in Phase 1 NIH-sponsored trial
Feb 23, 2021: Monoclonal antibody REGN3048 against MERS coronavirus show promise in Phase 1 NIH-sponsored trial
Jan 27, 2020: Pulmotect’s PUL-042 shows promising pre-clinical efficacy in preventing lethal coronavirus infection
Dec 20, 2019: New MERS vaccine clinical trial starts in Saudi Arabia
Sep 29, 2018: Vaccitech licenses MERS rights to Oxford University: CEPI awards contract worth up to USD$19 million to Oxford University and Janssen vaccines to develop MERS, Lassa, and Nipah vaccines
Mar 05, 2018: Hemispherx to Present Alferon N Injection at the 30th Annual ROTH Conference
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Middle East Respiratory Syndrome (MERS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Middle East Respiratory Syndrome (MERS) - Dormant Projects, 2022
Middle East Respiratory Syndrome (MERS) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Middle East Respiratory Syndrome (MERS), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
